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Abstract: Hepatocellular carcinoma (HCC) is the fifth most common neoplasm and a major cause of
cancer-related death worldwide. There is no ideal biomarker allowing early diagnosis of HCC and tu-
mor surveillance in patients receiving therapy. Liquid biopsy, and particularly circulating tumor cells
(CTCs), have emerged as a useful tool for diagnosis and monitoring therapeutic responses in different
tumors. In the present manuscript, we evaluate the current evidence supporting the quantitative and
qualitative assessment of CTCs as potential biomarkers of HCC, as well as technical aspects related
to isolation, identification, and classification of CTCs. Although the dynamic assessment of CTCs
in patients with HCC may aid the decision-making process, there are still many uncertainties and
technical caveats to be solved before this methodology has a true impact on clinical practice guide-
lines. More studies are needed to identify the optimal combination of surface markers, to increase the
efficiency of ex-vivo expansion of CTCs, or even to target CTCs as a potential therapeutic strategy to
prevent HCC recurrence after surgery or to hamper tumor progression and extrahepatic spreading.
Keywords: hepatocellular carcinoma; liquid biopsy; circulating tumor cells; dynamic changes;
therapeutic target
1. Introduction
Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer, repre-
senting 90% of primary liver malignancies in patients with cirrhosis. According to the
World Health Organization, HCC is the fifth most common neoplasm worldwide and the
third leading cause of cancer-related death [1,2]. The geographic distribution of HCC is
very heterogeneous and closely associated with the prevalence of the different etiologies
of chronic liver disease [3–5]. In recent decades, different healthcare strategies such as
vaccination campaigns, development, and liberal prescription of direct-acting antivirals
against hepatitis C, and promotion of healthy lifestyle, have been implemented to reduce
the incidence of HCC [5,6], but liver cirrhosis is still prevalent and forms a major driver of
HCC [7]. The Barcelona Clinic Liver Cancer (BCLC) classification is nowadays the most
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widely used staging system of HCC [8,9], which also provides therapeutic guidance, and it
has been recommended by international clinical practice guidelines [5,10]. Patients with
early-stage HCC (BCLC 0-A) may be candidates for potentially curative therapies such as
radiofrequency ablation, surgical liver resection (LR), or liver transplantation (LT), with
5-year survival rates of 50–80%. On the other hand, patients with advanced HCC (BCLC
C) are candidates for systemic therapies, mainly (multi) tyrosine kinase inhibitors such as
sorafenib or regorafenib, and the more recently approved combination of atezolizumab
(anti-programmed death-ligand 1 -PD-L1- monoclonal antibody) and bevacizumab (anti-
vascular endothelial growth factor monoclonal antibody), which may provide median
survival rates shorter than 2 years [4].
Therefore, early diagnosis of HCC is paramount in patients with liver cirrhosis to max-
imize survival [11,12]. Nowadays, patients with advanced liver fibrosis or cirrhosis may
undergo screening for HCC, which consists of an abdominal ultrasound every six months.
Serum biomarkers of HCC such as alpha-fetoprotein (AFP), AFP-L3 (a glycoform of AFP),
des-gamma-carboxyprothrombin, glypican-3 (GPC3), or osteopontin [13] may provide
information about the biological aggressiveness of HCC but, unfortunately, they are not
sufficiently accurate to form part of screening strategies. There is a need for new biomarkers
of HCC to refine screening and diagnosis, to better predict tumor recurrence after surgical
or ablative therapies, and to monitor response in patients receiving systemic therapies. In
the present review, we have comprehensively evaluated the current evidence supporting
the quantitative and qualitative assessment of circulating tumor cells (CTCs) as potential
biomarkers of HCC.
2. Liquid Biopsy and CTCs
The term liquid biopsy refers to the detection of cancer byproducts mainly in the
bloodstream which could provide first-hand information about the features of the primary
tumor from which they belong. Liquid biopsy offers promising benefits in terms of refined
diagnosis, prognostic stratification, and therapeutic guidance in different types of cancers
such as metastatic breast, colorectal, or prostate cancer [13]. There are several modalities
of liquid biopsy, including the detection of CTCs, extracellular vesicles, or circulating
tumor nucleic acids (ribonucleic acid -RNA-, microRNA -miRNA-, tumor deoxyribonucleic
acid -DNA-). The most evident advantage of liquid biopsy is the broadly accessible
study specimens, which usually consist of peripheral blood samples [14]. CTCs were first
described in 1869 as malignant cells derived from the primary or metastatic tumor, able
to access the systemic circulation [15,16]. They are very scarce in peripheral blood, with a
very short circulating half-life (1 h to 2.4 h) [17]. Despite this, CTCs can be detected even at
earlier tumor stages, being associated with a more aggressive biological behavior. Unlike
other liquid biopsy markers such as cell-free DNA, CTCs are unequivocally associated with
the presence of viable tumors (even if not detected by conventional imaging techniques)
and the progressive increase of CTCs indicates tumor spreading recurrence and metastases.
Prior to the identification of CTCs, blood samples require an enrichment method to
purify such a minority cell population. Methods for CTC enrichment may be classified into
positive and negative. These are not mutually exclusive and can therefore be combined to
optimize the capture of CTCs. Negative-enrichment methods are based on the removal of
white blood cells by antibody-based depletion strategies usually based on anti-CD45-coated
magnetic beads or CD45 depletion cocktails. Enriched CTCs can be detected afterward by
several different methodologies such as immunocytochemistry (ICC) [18–23], quantitative
real-time polymerase chain reaction (PCR) [24–26], flow cytometry, or immunofluorescence
in situ hybridization (iFISH) [27–32], which may combine several probes or antibodies
to identify different CTC subpopulations. In contrast, positive-enrichment methods take
advantage of specific biological and physical properties of CTCs to distinguish them
from non-tumoral blood cells. Physical enrichment strategies are frequently based on
centrifugation and microfiltration [33–50] to selectively isolate CTCs according to their
differential density and size, respectively [51]. Among all the positive-enrichment methods,
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immunoaffinity is the most widely used but the optimal biomarker matching all CTC
subpopulations is unknown. Different combinations of antibodies can be immobilized on
the surface of magnetic particles or microdevices with increased capture efficiency [51,52].
As with negative-enrichment methods, isolated CTCs can be subsequently identified by
common methodologies (Figure 1). The sensitivity for the detection of CTCs varies greatly
between the different methods used, and even between different studies that use the
same methodology.
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The only CTC detection system approved by the Food-and-Drug Administration
is the CellSearch® system (Menarini-Silicon Biosystems, Bologna, Italy), which is based
on immunocaptur (positive enrichment) of CTCs expressing epithelial-to-cell adhesion
molecule (EpCAM+ CTCs). Although the ellSearch® system has been widely used in
HCC research with promising results [26,53–62], novel methodologies are in the pipeline
claiming for increased CTC detection rate, sensitivity, and specificity [30,35,63,64]. Thus,
CTC analysis by the IsoFlux® system [64] or by negative enrichment and iFISH [30] showed
an i creased sensitivity in HCC candidates for LT compared to the CellSearch® system
(90.5% vs. 4.7% and 70% vs. 26.67%, respectively).
3. Surface Markers to Identify CTCs in HCC and Clinical Significance
The key to ensuring adequate sensitivity and specificity is to identify a surface marker
to be targeted for optimal positive cell identification. Recent advances have shown that
there is no single optimal marker, and probably the best appro ch is to combi e different
surface markers with additional selection filters according to physical properties. In this
section, we provide an insight into the most widely used CTC markers in HCC with their
benefits and limitations.
3.1. Liver and HCC Specific Markers
A logical source of candidate markers for the detection of CTCs in HCC is the liver-
specific or HCC-specific proteome. Since hepatocytes do not circulate under physiological
conditions, any cell expressing a liver or HCC-specific marker detected in the bloodstream
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may be considered a potential CTC. GPC3 is a cell membrane-anchored protein currently
used in clinical practice for HCC pathological analysis and characterization [65]. Since
GPC3 is more frequently observed in moderately and poorly differentiated HCC tumor
cells, which are more prone for extrahepatic spreading, the presence of GPC3+ CTCs
may inform about a de-differentiated metastatic HCC. Thus, the immunomagnetic enrich-
ment of GPC3+ CTCs and subsequent analysis by fluorescent activated cell sorter with
anti-cytokeratin (CK, an epithelial marker) antibodies was postulated as a valid method-
ology to identify poor prognostic HCC patients. Indeed, an increased number of CTCs
obtained by this approach was associated with microvascular invasion (a well-known
poor prognostic histological feature [66]), increased tumor recurrence rates, and shorter
overall survival [67]. Asialoglycoprotein receptor (ASGPR) is a transmembrane protein
exclusively expressed on the surface of hepatocytes [68], but unlike GPC3, it is highly ex-
pressed in well-differentiated HCC. Xu et al. developed a system based on magnetic beads
to capture ASGPR+ CTCs, which were subsequently identified by ICC with antibodies
anti-hepatocyte-specific hepatocyte paraffin 1 (HepPar 1; a marker for differential diagnosis
of HCC [69]) or anti-CK alone. The positivity rate and the number of CTCs isolated by this
technique were associated with increased tumor burden, macrovascular invasion, and poor
histological differentiation [70]. This methodology was modified afterward using a new
anti-ASGPR monoclonal antibody for the isolation of CTCs and a combination of anti-CK
and anti-CPS1 (an antigen for HepPar 1) antibodies, thus resulting in higher sensitivity for
CTC detection (89% vs. 81%) [71]. The authors designed a platform to capture and release
living HCC CTCs for their ulterior expansion in a 3D cell culture assay [72]. The combi-
nation of EpCAM, ASGPR, and GPC3 antibodies in the so-called NanoVelcro CTC Assay
resulted in HCC CTCs detection in up to 97.6% of patients with HCC at various stages,
being the number of CTCs associated with clinical outcomes. In addition, the NanoVelcro
CTC Assay identified a vimentin-positive subpopulation of CTCs that indicated a partic-
ularly aggressive biological tumor behavior [52]. Using a labyrinth device that exploits
the physical characteristics of CTCs and a combination of HCC-specific antibodies against
GPC3, glutamine synthetase, and HepPar-1 for ICC analysis, Wan et al. detected CTCs
in 88.1% of patients with HCC and correlated the positivity rate of CTCs with the tumor
stage [73]. Liver-specific or HCC-specific markers could also be useful for the identification
of HCC CTCs after removal of CD45+ cells and/or red blood cells. Immunofluorescence
analysis of negative-enriched CTCs from HCC patients with antibodies against ASGPR
and CPS1 or GPC3 showed high sensitivity and specificity for detecting CTCs and could
provide relevant prognostic information [18,74]. Thus, the incorporation of several specific
markers into a single platform for the isolation and/or detection of HCC CTCs across all
tumor stages may be more efficient than a single marker.
3.2. Epithelial Markers
EpCAM is one of the most used membrane-associated proteins for capturing CTCs
in peripheral blood samples as it is not expressed by normal blood cells [75]. EpCAM+
CTCs have been associated with different clinicopathological features of HCC, including
vascular invasion, high serum AFP (≥400 ng/mL), and more advanced BCLC stage [58,59].
In patients undergoing LT, LR, transarterial chemoembolization (TACE), or radiotherapy
for HCC, EpCAM+ CTC count at baseline has been associated with increased tumor
recurrence, shorter overall survival, and shorter progression-free survival [26,54,55,60].
EpCAM+ CTCs could also aid to assess the optimal surgical margin size during LR [62],
optimizing the management of HCC patients on the waiting list for LT [76], and for a
better selection of candidates to certain therapies [61]. In other words, EpCAM+ CTCs are
strongly correlated with tumor aggressiveness and could assist in the adequate stratification
of HCC patients for optimal therapy and in predicting their response to treatment [56].
Unfortunately, EpCAM-based CTC enrichment may overlook CTCs with low expression of
the epithelial marker [77,78] or those which expression has been lost during the dynamic
process of epithelial-to-mesenchymal transition (EMT) [75,79]. Thus, the use of additional
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criteria such as size and brightfield image could enhance CTC detection sensitivity in
HCC [22]. In addition, since EpCAM has been identified as a surface marker of HCC cells
displaying stem cell features [80,81] and EpCAM+ CTCs from HCC patients are highly
tumorigenic in vivo [60], it is possible that EpCAM+ CTCs account for both tumorigenic
and non-tumorigenic cells.
3.3. Epithelial-to-Mesenchymal Transition Markers
The EMT is the process by which a CTC with an epithelial phenotype acquires mes-
enchymal characteristics that confer increased migratory ability, invasiveness and/or drug
resistance, thus contributing to HCC spreading [82]. The activation of the EMT process in
CTCs occurs primarily in the bloodstream and involves dynamic adaptive mechanisms that
are associated with stress response, cell cycle, or immune evasion [21,40,83,84]. This process
may not be considered dichotomous: CTCs do not necessarily exist in ‘pure’ epithelial or
mesenchymal states. CTCs can be found in intermediate states showing characteristics of
both epithelial and mesenchymal phenotypes [85]. Therefore, the use of a combination
of epithelial and mesenchymal markers would improve the sensitivity and the overall
accuracy of a CTC enrichment method. The expression of EMT markers such as vimentin,
twist, Zinc finger E-box-binding (ZEB)1, ZEB2, snail, slug, and E-cadherin has been studied
in liver-derived CTCs from HCC patients, being the co-expression of twist and vimentin
significantly correlated with tumor burden, macrovascular invasion, and more advanced
stages [86]. The CanPatrolTM system, which combines a positive-enrichment filter-based
method and an RNA-in situ hybridization (RNA-ISH) technique, was able to stratify CTCs
into three phenotypic subgroups accordingly to the predominantly expressed markers:
epithelial phenotype (EpCAM, CK 8/18/19), mesenchymal phenotype (vimentin, twist),
and mixed/hybrid phenotype. Overall CTC count (which comprises all phenotypes) per-
formed better than serum AFP to discriminate between patients diagnosed with HCC and
those with non-malignant liver diseases [44]. Mesenchymal CTCs (mCTC) and mixed
CTCs were associated with clinical features indicating poor prognoses, such as high serum
AFP levels, advanced tumor stages, and microvascular invasion. Thus, EMT-based classi-
fication of CTCs could predict early recurrence of HCC, metastases, and shorter overall
survival [33,36,40,43,45,48,50].
Epithelial CTCs and mCTC are occasionally found in the bloodstream bound to
immune cells, platelets, and fibroblast as circulating tumor microemboli or CTC clusters,
which may arise from the detachment of multicellular aggregates from the primary tumor
mass or the reaggregation of CTCs in the bloodstream [84]. These clusters contribute to
the survival and adoption of invasive advantages of CTCs and highlight the relevance of
the tumor environment in the metastatic process [87,88]. The microfluidic isolation and
subsequent immunofluorescence identification of CTC clusters in HCC patients with more
advanced tumor stages indicated their association with tumor progression [73]. By using
the CanPatrolTM system, Luo et al. showed that the presence of CTC clusters consisting
of CTCs (epithelial and/or mesenchymal) and white blood cells was associated with
tumor burden and vascular invasion, being an independent predictor of poor prognosis
in HCC [41]. In addition, the authors correlated the number of mCTC and CTC clusters
with a specific mutational profile of EMT-related genes involved in the metastatic process
of HCC [42].
3.4. Stem-Cells Markers
Stem cell markers are expressed in a small subpopulation of CTCs which may be
considered tumor-initiating cells related to increased aggressiveness and poor prognosis.
These circulating cancer stem cells (cCSC) may derive directly from the tumor or an
adaptive process during the EMT. Due to its scarcity in peripheral blood, CTC-derived
xenograft models and CTC-derived ex vivo cultures have been used for the study of
cCSC [89]. CSCs may express surface markers of regular stem cells such as EpCAM, CD133,
CD44, CD90, or ICAM-1. CD44 is an adhesion molecule that facilitates tumor cell invasion
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and migration [90] and it is concomitantly expressed with other stem-cell markers. In HCC
cells and tumor xenograft models, CD133+CD44+ cells (but not CD133+CD44-) display
stem cell properties, including extensive proliferation, self-renewal capacity, tumorigenic
potential, resistance to chemotherapy, and expression of stem cell-associated genes [91]. In
this sense, CD133+CD44+ cCSC has been correlated with increased serum transaminases,
serum AFP and poorer outcomes in HCC patients [92]. CD90+CD44+ cells represent a more
aggressive cell subpopulation within the CD90+ group, with increased in vivo tumorigenic
capacity than CD90+CD44- cells. Interestingly, CD90+ CTCs express higher levels of
CD44 than those cells located within the primary tumor, suggesting increased tumor
aggressiveness. Indeed, the number of CD90+ cCSC was related to disease progression in
HCC patients [93]. The concomitant expression of CD90 with other surface markers such
as CXCR4 (receptor for stromal cell-derived factor-1 (SDF-1/CXCL12)) may be required by
cCSC to motivate HCC progression [94]. EpCAM+ CTCs from HCC patients exhibit high
tumorigenic activity in vivo and were associated with the expression of others CSC markers
such as CD133 and ABCG2 [60]. Based on a strategy combining negative cell enrichment
and quantitative real-time PCR, the expression of nine CSC markers was analyzed in the
blood of HCC patients. Aligning with the above-referred studies, EpCAM, CD133, CD90,
and CK19 (another hepatic stem marker [95]) were significantly overexpressed in the HCC
group and associated with the presence of a corresponding subpopulation of HCC CTCs
and with a higher tumor recurrence rate [25]. Similarly, EpCAM+CD90+ CTCs have been
associated with HCC recurrence after LT [96]. Although expression levels of ICAM-1 did
not differ significantly from the control group in that study, hepatic ICAM-1+ CTCs from
HCC patients show high tumorigenic activity in vivo and their frequency is an independent
risk factor of portal vein tumor thrombus and ascites [97].
4. Dynamic Changes of CTC Counts after HCC Therapy
Preoperative CTCs have been widely associated with HCC recurrence after
LR [24,36,55,56,60], LT [29,30,96] or local ablation [28]. Theoretically, a complete tumor re-
moval by LR or LT may motivate a rapid decline in CTC count in the post-operative period.
Similarly, local ablation therapies could release CTCs to the bloodstream initially, followed
by a progressive decline until complete clearance. In patients receiving systemic therapies,
the dynamic of CTC counts may vary depending on the therapeutic response. In any of
these situations, trends of CTC count after therapy could provide valuable information to
predict tumor recurrence or to anticipate resistance to systemic therapies (Figure 2).
4.1. CTC Dynamics after Liver Resection
Studies evaluating intraoperative CTC monitoring have shown that surgical ma-
nipulation during LR is not associated with a significant CTC release into the blood-
stream [49]. LR appeared to have little effect on CTC count in the immediate postoperative
period [53]. The decline of CTC count after surgical resection may be more evident be-
tween postoperative days 7 to 10 [40,49] and could continue declining up to the first
post-operative month [26,37,56,60]. The postoperative increase in CTCs and the persistence
of a high CTC count after LR may increase the risk of tumor recurrence and extrahepatic
metastases, as well as shorter overall survival. These results were consistent using the
CellSearch® [26,53,56,60] and the CanPatrolTM [37,40] systems, as well as the isolation by
size of epithelial tumor cells method [49]. It may well be that these patients with persistence
of CTCs had an incomplete tumor removal or additional HCC microscopic foci within the
liver, which in the last term would motivate local recurrence or distant metastases. The
percentage of mCTC (and total CTC count) could anticipate tumor recurrence or metastases
up to two months before it is evident in imaging techniques [40].
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4.2. CTC Dynamics after Liver Transplantation
LT is con idered a mor radical therapy than LR for patients with HCC since the
whole cirrhotic liver is removed, including the known HCC nodules and the possible
nascent tumors in the remaining liver parenchyma. A more rapid decline of CTCs would
therefore be expected. A single study using negative-enrichment and iFISH platform
showed a significant decrease in CTC count 3 months after surgery in most patients [30].
However, CTC dynamics assessed by the CanPatrolTM system did not find a significant
association with HCC recurrence [34]. More recently, Wang et al. reported that those
patients who did not have CTCs pre-LT and showed positive counts 2–4 weeks fter LT
had an increased risk of tumor recurrence [20]. This study used a negative-enrichment
method and ICC detection of CTCs and, unlike the results obtained by Xue et al. by
using iFISH [30], no significant difference in preoperative CTC count or CTC-positive
rate was observed between patients who experienced tumor recurrence and those who
did not. Very recently, Hwang et al. have shown that CTCs with cancer stemness could
predict HCC recurrence when they are detected preoperatively and 1 day after LT using
fluorescent activated cell sorter [96]. We have evaluated the clearance kinetics of CTCs in
HCC patients undergoing LT and found that the resence of CTC clusters before surgery
was associated with an incomplete cle ra ce of CTCs at postoperative day 30, which in
turn predicted mortality due to extrahepatic recurrence of HCC [98]. The unpredictable
evolutio of CTCs after LT could be in part explained using immunosuppressive drugs,
which are required to prevent graft rejection. Since evading the immune system is one
of the hallmarks of cancer [99], the use of immunosuppressive agents such as calcineurin
inhibitors may increase the risk of tumor recurrence in a dose-dependent manner [100].
A reduced CTC count after LT in a patient deeply im unosuppressed may be sufficient
to p rsist in the bloodstream l ading to tumor r currenc . Different protocols including
CTCs mo itoring have been proposed to decrease t e risk of tumor recurrence aft r LT
including the following aspects: (1) an adequate selection of recipients with limited tumor
burden and reduced baseline CTC count, (2) minimizing the handling of large HCCs during
transplantation to decrease the risk of CTC release, (3) decreasing liver graft ischemia-
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reperfusion injury to prevent the engraftment of CTCs in the liver and (4) consider using
anticancer drugs and (5) minimization of immunosuppression [101].
4.3. CTC Dynamics after Local Ablative Therapies and TACE
It has been suggested that radiofrequency ablation [46] and TACE [31,102] could
motivate the release of CTCs. Conversely, microwave ablation has been associated with a
significant decrease of CTCs and a higher tumoricidal effect [103]. Dynamic changes of
CTCs after radiofrequency ablation [39], chemoembolization [31,103,104], or microwave
ablation [39,103] seemed to have no impact on tumor recurrence rates when CTCs were
identified by using the CanPatrolTM system, negative-enrichment, and flow cytometry
or iFISH, and immunomagnetic enrichment. However, these studies were limited by the
reduced sample size. In a study including 155 HCC patients assessing CTCs by negative-
enrichment and iFISH, patients who responded to TACE (complete response and partial
response) had a significant CTC count decline whereas patients without radiological
response did not [32]. Similarly, when CTCs were assessed by the CellSearch® system,
patients with stable or decreasing CTC count one month after TACE or radiotherapy
showed radiological response or stable disease, while most of the patients with persistently
high CTC count showed disease progression [26].
4.4. CTC Dynamics during Systemic Treatment
There is no evidence regarding the dynamics of CTCs in patients with HCC receiving
multikinase inhibitors or immunotherapy. In a highly metastatic orthotopic nude mouse
model of green fluorescent protein-labeled HCC, Yan et al. used a non-invasive in vivo
flow cytometry method and showed that sorafenib could reduce the number of CTCs
by inhibiting tumor proliferation and angiogenesis [105]. A study evaluating cell-free
DNA has identified a mutational profile that indicates resistance to sorafenib [106]. More
reliable information could be obtained by analyzing the dynamic of CTC counts and by
characterizing the mutational profile of CTCs longitudinally to anticipate therapeutic
resistance and radiological progression, thus allowing patients to access a second-line
therapy in a timely manner.
5. Cell Culture of HCC CTCs
Ex vivo expansion of viable CTCs can be useful to obtain prognostic information
and to investigate the biochemical, gene expressional, and behavioral properties of the
primary cancer cells [107]. CTC culture would allow identifying specific targets for cancer
therapy, monitoring the acquisition of mutations conferring drug resistance, and even
testing the vulnerability of the tumor against multiple possible therapeutic agents in a
non-invasive manner [108]. Compared to preclinical CTC-derived xenograft models, the
ex vivo culture of CTCs is less time-consuming, which can be paramount when making
individualized clinical decisions [89]. Researchers frequently use 3D culture conditions
and the high glucose DMEM/F12 medium with epidermal growth factor and/or basic
fibroblast growth factor for the enrichment of cancer cell lines-derived CSC spheroids
in vitro [109,110]. Optional supplements are N2, B27, inhibitors Y27632 and SB431542,
heparin, insulin-transferrin-selenium, or fetal bovine serum. Even though, CTC culture
is challenging. Stable ex vivo culture of cCSC has been successfully achieved mainly in
patients with metastatic cancer and increased CTC count [111,112], but CSC spheroids
often survive for only a few days or weeks [113]. Therefore, ex vivo CTC expansion is
inefficient even in patients with advanced cancer [114,115].
Ex vivo culture of cCSC in patients with HCC has been reported even more anecdotally.
The few successful studies included intermediate/advanced cancer patients and reported
similar culture conditions including normoxia, MatrigelTM solution, and DMEM (with or
without 10% fetal bovine serum). cCSC isolation methods varied widely, including negative
selection with magnetic beads [23,116] and positive selection by microfluidic chip [72] or
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fluorescent activated cell sorter [117]. A success rate of 86% to 100% has been reported with
a median cell survival time of 7–14 days, although a publication bias is highly probable.
The main caveat for CTC culture is again the reduced number of these cells in the
bloodstream. Different approaches are under investigation to increase the isolation rate of
CTCs [118]. New methodologies for stable ex vivo culture of CTCs will need to mirror the
tumor microenvironment as accurately as possible. Stress conditions naturally occurring in
solid tumors such as glucose depletion and hypoxia have been tested. Glucose deprivation
slows down cell proliferation but increases the expression of stem cell markers and other
stem cell phenotypic characteristics [119]. Regarding the oxygenation conditions, the cul-
ture of cCSC has been successfully achieved both in normoxia and hypoxia. Hypoxia is a
critical microenvironmental factor promoting the self-renewal of CSCs and a more aggres-
sive phenotype in tumor cells [83,110,111,120], which in turn is associated with resistance
to therapy [121,122]. Hypoxic conditions have been successfully used for long-term CTC
culture from patients with different types of cancer including colorectal [123], lung [124],
breast [89,108], or gastroesophageal [125] tumors. In an ongoing research project analyzing
the clearance of CTCs after local ablation of HCC, we tried to obtain cCSC spheroids by
using different strategies. First, we used anti-EpCAM-coated immunomagnetic beads
and the IsoFlux® system (Fluxion Biosciences, Alameda, CA, USA), which displays great
sensitivity in the identification of HCC-derived CTCs [64]. Although we were able to obtain
CSC spheres from established HCC cell lines using this strategy, we failed to obtain cCSC
spheroids in any of the 14 patients analyzed after 2 weeks of cell culture in normoxia, high
glucose, and ultra-low adherence. By contrast, in an independent cohort of 12 patients, the
negative enrichment and subsequent culture of CD45- CTCs under the same conditions
allowed to obtain CSC-like spheroids in 50% of patients. Despite this encouraging result,
spheroids could not be expanded for more than 7–10 days and they finally died off after
this period (data not shown). In addition to the difficulties of cultivating CTCs, it is worth
mentioning that most patients included in this study were intermediate-stage HCC patients,
with lower CTC counts than those obtained in advanced HCC.
6. CTCs and Microenvironment as Therapeutic Targets in HCC
Targeting CTCs is an attractive strategy to hamper tumor progression. Indeed, the
development of tumor cell populations with metastatic potential is a critical hallmark of
cancer. There are several therapeutic strategies directed against the tumor microenviron-
ment to avoid CTC survival and differentiation to more aggressive phenotypes, which are
shown in Table 1.
Table 1. Potential strategies to target CTCs or tumor microenvironment to prevent HCC recurrence and metastases. The
table includes systemic treatments, physical removal methods, and strategies based on gene therapy and immunotherapy.
Methodology
/Therapy Target Study Population Key Findings
Sorafenib pERK+/pAkt− CTCs HCC patients pERK+/pAkt− CTCs are sensible to sorafenib [23].
Viatar System
EpCAM+ CTCs
Physical removing of CTCs. It requires a dialysis system. Proof
of concepts.
TIIAS In vitro,canine model
Miniaturized Viatar System. Portable aphaeretic system. It
analyzes 1–2% of whole blood in 2 hours [126].
FSMW Cancer patients Passive CTC-capturing device. Estimated analysis of 1.5–3 litersof blood in 30 min [127].
BPAFIC In vitro,rabbit model
Passive CTC-capturing device. Captures 2.1% of CTCs in 5 min
and kills them with 100% efficiency [128].
Anti-PD-1 PD-L1+ CTCs HCC patients Favorable response to anti-PD-1 therapy is associated with thepresence of PD-L1+ CTCs [129].
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Table 1. Cont.
Methodology
/Therapy Target Study Population Key Findings
Anti-EGFR CTCs (angiogenesis,cell migration) Mouse model
EGFR inhibition may reduce CTCs after transarterial
chemoembolization [130].
Anti-MVP MVP+ CTCs In vitro Anti-MVP therapy target MVP
+EpCAM− CTCs, which are
related to metastases [19].
Anti-CD44 CD90+CD44+ CSCs In vitro CD44 blockade could induce the death of CD90+ cells [131].
AR overex-
pression CD90 expression Mouse model
Enhancing AR expression in CTCs might reduce the risk of HCC
recurrence [132].
Anti-USP1 USP1+ CTCs Mouse model
USP1 upregulation in CTCs correlates with metastases and
reduced survival. USP1 inhibition is a potential therapy for HCC
[133].
Anti-ICAM-1 ICAM-1+ CTCs Mouse model Inhibition of ICAM-1 reduces tumor initiation and metastases[97].
Anti-TM4SF5 TM4SF5+ CTCs Mouse model Targeting TM4SF5 or interaction between TM4SF5 and CD44 maylead to efficient inhibition of TM4SF5-mediated metastases [134].




CXCR4+ CTCs In vitro, mousemodel
STAT3 inhibition and CXCR4 blockade have clinical therapeutic
potential in HCC [136]; Hepatic stellate cells play an important
role in liver metastases by releasing SDF-1 [137,138].








Tumor-derived exosomal miR-1247-3p converts fibroblasts to
cancer-associated fibroblasts which promote tumor stemness,







MiR-155 is highly elevated in EpCAM+HCC cells and could be
an actionable target to remove the EpCAM+CSC
population [141].
Anti-SMAD3 CTCs In vitro, mousemodel
SMAD3-containing exosomes from primary tumors could favor
the viability and adhesion of CTCs and the risk of
metastases [142].
Function
modulation LSECs In vitro
Cancer-activated LSECs can enhance the proliferation of Tregs







Chemokine CCL5 recruits regulatory T cells to facilitate the
immune escape of CTCs [21].
IFN-α Microenvironment Mouse model IFN-α does not decrease the number of CTCs but could modulatethe tissue microenvironment to resist CTCs and metastases [144].
TIIAS, Temporary Indwelling Intravascular Aphaeretic System; FSMW, Structured and Functionali-zed Medical Wire; BPAFIC, Black Phosphorus and
Antibody Functionalized Intravenous Catheter; AR, Androgen receptor; CCR, colorec-tal cancer; EMT, Epithelial-Mesenchymal Transition; LSECs,
Liver sinusoidal endothelial cells; Tregs, regulatory T cells.
6.1. CTCs as Therapeutic Targets in HCC
The approved multikinase inhibitors for advanced HCC may affect the viability of
CTCs. Adjuvant therapy with sorafenib after surgical resection could eliminate residual
CTCs to reduce the risk of postoperative recurrence and metastases [145]. pERK+/pAkt−
CTCs are vulnerable to sorafenib and their clearance is associated with improved progression-
free survival [23]. However, the most effective therapy against CTCs would be their
physical removal before they can migrate to other organs and produce metastases. The
Viatar cancer dialysis system (Viatar CTC Solutions Inc., Lowell, MA, USA), the temporary
indwelling intravascular CTC isolation system [126], the GILUPI CellCollector® [127] or
the black phosphorus and antibody-functionalized intravenous catheter [128] are different
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technologies designed for in vivo removal and destruction of EpCAM+ CTCs [128]. Most
of them were designed to allow the screening of a large volume of blood and they could be
used as adjuvant therapies after surgical resection or locoregional ablation. Although each
of these systems claims for inherent technical advantages, additional studies are needed to
determine their safety and efficacy in vivo.
Gene therapy and immunotherapy have also been proposed as promising tools to selec-
tively target resistant subpopulations of CTCs. Immune checkpoint inhibitors in combina-
tion with epidermal growth factor receptor (EGFR) inhibitors (atezolizumab/bevacizumab)
have recently become first-line therapies in patients with advanced HCC, as they have
demonstrated improved progression-free and overall survival rates as compared with
sorafenib, the previous standard of care [146]. Anti-programmed cell death protein
1 (PD-1) therapy could target PD-L1+ CTCs, which are associated with more aggressive dis-
ease [129]. Inhibition of EGFR signaling reduces total CTC count and metastases after local
ablation [130,147]. There are other potential therapeutic targets able to interfere with the
viability of CTCs which could reshape future therapeutic algorithms in HCC. Major vault
protein (MVP) depletion by siRNA technology or by anti-MVP antibodies reduces survival,
migratory capacity, and invasiveness of HCC cells [19]. Other strategies to target CTCs,
either as a whole population or as subpopulations with particularly aggressive phenotypes
are depletion of ubiquitin-specific protease 1 [133], inhibition of Intercellular Adhesion
Molecule 1 (ICAM-1) using a plasmid expressing a short hairpin RNA [97], blockade of
CD44 by specific antibodies [93,131] and promotion of the expression of androgen receptor,
which suppresses CD90 expression and cell migration and increases cell death [132].
Interfering with the EMT activation or the colonization of CTCs could be therapeuti-
cally attractive to prevent the extrahepatic spread of HCC [84,134]. Tacrolimus, an immuno-
suppressant commonly used to prevent allograft rejection after LT, has been associated with
the induction of motility and invasiveness of HCC cells in vitro and it is able to increase the
risk of tumor recurrence in a dose-dependent manner [100]. One of the main mechanisms
underlying this clinical observation is the activation of the Rho/ROCK signaling pathway.
The administration of Y-27632, a ROCK-specific inhibitor, prevents tumor recurrence after
LT in an animal model of HCC [135,148]. However, this mechanism should be further
investigated since ROCK inhibition also promotes survival and expansion of tumor stem
cells in vitro [149].
6.2. Tumor Microenvironment as a Therapeutic Target in HCC
Many interactions or communication factors are forming the pre-metastatic niche,
which promotes the arrival, survival, and growth of tumor cells. Targeting this crosstalk
could prevent extrahepatic spreading of HCC. The SDF-1/CXCR4 axis participates in the
acquisition of stemness and migratory potential of HCC cells and could be considered a
potential target to prevent metastases [136], with promising results obtained in preclinical
studies targeting CXCR4 [137,138] or SDF-1 [139] by specific inhibitors or gene expressing
traps respectively. MiRNAs can be released by many cell types into the extracellular space
where they regulate different processes. Thus, the tumor-derived exosomal miR-1247-3p
transforms fibroblasts into cancer-associated fibroblasts to promote lung metastases of liver
cancer [140]. MiR-155 released in exosomes by HCC cells stimulates cell colony formation,
migration, and invasion in vitro [141] and promotes HCC proliferation in vivo [150]. Simi-
larly, SMAD Family Member 3-enriched exosomes derived from primary tumors promote
the metastatic potential of CTCs [142].
Other interactions between CTCs and the tumor microenvironment involve the im-
mune system [151–153], and particularly the adhesive myeloid-derived suppressor cells,
tumor-associated macrophages, and regulatory T cells (Tregs). These interactions protect
CTCs from immune responses, thus increasing their metastatic potential. Liver sinusoidal
endothelial cells are the major liver cell type responsible for TGF-β-dependent hepatic
Treg induction and immune tolerance [154]. The immunosuppressive chemokine CCL5
recruits Tregs to the tumor microenvironment to promote immune escape [155]. This may
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explain the correlation between the number of Tregs and CTC count [24]. Moreover, Treg
could in turn induce CCL5 expression in CTCs by secretion of TGF-β1 [21]. Targeting liver
sinusoidal endothelial cells [143] or blocking the CCL5 pathway [21,155] could interfere
in this feedback, thus inducing a hostile microenvironment [144] which hampers CTC
survival and metastatic colonization.
7. Future Perspectives
Liquid biopsy, and particularly quantitative and qualitative assessment of CTCs, will
probably reshape the future diagnostic and therapeutic algorithms of HCC. This valuable
information may be easily obtained from low-volume peripheral blood samples, either
with diagnostic, therapeutic purposes or even to stratify patients according to the biological
aggressiveness of the primary tumor. However, current methodologies pose important
caveats which need to be addressed before this technology is implemented in routine
clinical practice. First, the optimal combination of markers for the enrichment of CTCs,
able to detect only viable cells with metastatic potential, is unknown. Most studies have a
limited sample size, lack external validation and their results become obsolete shortly after
their publication due to the vertiginous technological development. Secondly, isolating
CTCs for ulterior culture and evaluation of their mutational profile is challenging and
very inefficient under current strategies. The development of optimal culture conditions
to expand CTCs is paramount to evaluate their resistance to available therapies and to
advance towards truly personalized medicine in HCC. Finally, CTC counting is a time-
consuming process that requires highly specialized personnel and expensive technology.
Blood samples should be analyzed as soon as possible after the extraction and storing
samples longer than 24 h could threaten the viability of CTCs. The whole process should
be automatized, and costs reduced so this technology is made available in all institutions
taking care of patients with HCC. Only then, liquid biopsy could be incorporated as part of
the diagnostic and therapeutic armamentarium of HCC.
Author Contributions: Conceptualization, M.D.l.M., M.R.-P. and G.F.; literature search, M.L.E.-C.,
S.G.-R., J.Z.-O., V.A.-T., R.A., M.S.-F., R.C., M.R.-P. and G.F.; writing—original draft preparation,
M.L.E.-C., S.G.-R., M.R.-P. and G.F.; writing—review and editing, G.F. and M.R.-P. All authors have
read and agreed to the published version of the manuscript.
Funding: This work was supported by the “Plan Nacional de I+D+I Proyectos de Investigación
en Salud of Instituto de Salud Carlos III (ISCIII), Subdirección General de Evaluación and Fondo
Europeo de Desarrollo Regional (FEDER)” (grant number PI18/01736). G.F. was supported by the
CIBERehd. S.G.-R. is supported by the “Consejería de Salud y Familias de la Junta de Andalucía and
Fondo Social Europeo” (grant number RH-0075-2020). M.L.E.-C. was supported by the ISCIII (grant
number FI19/00357).
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design
of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or
in the decision to publish the results.
References
1. Marrero, J.A.; Kulik, L.M.; Sirlin, C.B.; Zhu, A.X.; Finn, R.S.; Abecassis, M.M.; Roberts, L.R.; Heimbach, J.K. Diagnosis, Staging,
and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver
Diseases. Hepatology 2018, 68, 723–750. [CrossRef] [PubMed]
2. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of
incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [CrossRef] [PubMed]
3. Reig, M.; Forner, A.; Ávila, M.A.; Ayuso, C.; Mínguez, B.; Varela, M.; Bilbao, I.; Bilbao, J.I.; Burrel, M.; Bustamante, J.; et al.
Diagnosis and Treatment of Hepatocellular Carcinoma. Update of the Consensus Document of the AEEH, AEC, SEOM, SERAM,
SERVEI, and SETH. Medicina Clínica 2021, 156, 463.e1–463.e30. [CrossRef]
4. Llovet, J.M.; Kelley, R.K.; Villanueva, A.; Singal, A.G.; Pikarsky, E.; Roayaie, S.; Lencioni, R.; Koike, K.; Zucman-Rossi, J.; Finn, R.S.
Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 2021, 7, 6. [CrossRef]
5. Forner, A.; Reig, M.; Bruix, J. Hepatocellular carcinoma. Lancet 2018, 391, 1301–1314. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 13073 13 of 19
6. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J.
Hepatol. 2018, 69, 182–236. [CrossRef] [PubMed]
7. Hernandez–Gea, V.; Toffanin, S.; Friedman, S.L.; Llovet, J.M. Role of the Microenvironment in the Pathogenesis and Treatment of
Hepatocellular Carcinoma. Gastroenterology 2013, 144, 512–527. [CrossRef] [PubMed]
8. Llovet, J.M.; Brú, C.; Bruix, J. Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification. Semin. Liver Dis. 1999, 19,
329–338. [CrossRef] [PubMed]
9. Reig, M.; Darnell, A.; Forner, A.; Rimola, J.; Ayuso, C.; Bruix, J. Systemic Therapy for Hepatocellular Carcinoma: The Issue of
Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST. Semin. Liver Dis. 2014, 34, 444–455.
[CrossRef]
10. European Association for the Study of the Liver. European Organisation for Research and Treatment of Cancer. EASL–EORTC
clinical practice guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2012, 56, 908–943. [CrossRef] [PubMed]
11. Yang, J.D.; Kim, W.R. Surveillance for Hepatocellular Carcinoma in Patients with Cirrhosis. Clin. Gastroenterol. Hepatol. 2012, 10,
16–21. [CrossRef]
12. Yang, J.D.; Mannalithara, A.; Piscitello, A.J.; Kisiel, J.B.; Gores, G.J.; Roberts, L.R.; Kim, W.R. Impact of surveillance for
hepatocellular carcinoma on survival in patients with compensated cirrhosis. Hepatology 2018, 68, 78–88. [CrossRef]
13. Mocan, T.; Simão, A.L.; Castro, R.E.; Rodrigues, C.M.P.; Słomka, A.; Wang, B.; Strassburg, C.; Wöhler, A.; Willms, A.G.; Kornek, M.
Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning? J. Clin. Med. 2020, 9, 1541. [CrossRef] [PubMed]
14. Von Felden, J.; Garcia-Lezana, T.; Schulze, K.; Losic, B.; Villanueva, A. Liquid biopsy in the clinical management of hepatocellular
carcinoma. Gut 2020, 69, 2025–2034. [CrossRef] [PubMed]
15. Ashworth, T.R. A Case of Cancer in Which Cells Similar to Those in the Tumours Were Seen in the Blood after Death. Aust. Med.
J. 1869, 14, 146.
16. Parkinson, D.R.; Dracopoli, N.; Petty, B.G.; Compton, C.; Cristofanilli, M.; Deisseroth, A.; Hayes, D.F.; Kapke, G.; Kumar, P.; Lee,
J.S.; et al. Considerations in the development of circulating tumor cell technology for clinical use. J. Transl. Med. 2012, 10, 138.
[CrossRef] [PubMed]
17. Okajima, W.; Komatsu, S.; Ichikawa, D.; Miyamae, M.; Ohashi, T.; Imamura, T.; Kiuchi, J.; Nishibeppu, K.; Arita, T.; Konishi,
H.; et al. Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids. World J.
Gastroenterol. 2017, 23, 5650–5668. [CrossRef] [PubMed]
18. Liu, H.-Y.; Qian, H.-H.; Zhang, X.-F.; Li, J.; Yang, X.; Sun, B.; Ma, J.-Y.; Chen, L.; Yin, Z.-F. Improved method increases sensitivity
for circulating hepatocellular carcinoma cells. World J. Gastroenterol. 2015, 21, 2918–2925. [CrossRef]
19. Lee, H.M.; Joh, J.W.; Seong, C.G.; Kim, W.-T.; Kim, M.K.; Choi, H.S.; Kim, S.Y.; Jang, Y.-J.; Sinn, D.H.; Choi, G.S.; et al. Cell-surface
major vault protein promotes cancer progression through harboring mesenchymal and intermediate circulating tumor cells in
hepatocellular carcinomas. Sci. Rep. 2017, 7, 13201. [CrossRef] [PubMed]
20. Wang, P.; Xu, Y.; Sun, Y.; Cheng, J.; Zhou, K.; Wu, S.; Hu, B.; Zhang, Z.; Guo, W.; Cao, Y.; et al. Detection of circulating tumour
cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation. Liver Int. 2021, 41,
562–573. [CrossRef]
21. Sun, Y.-F.; Wu, L.; Liu, S.-P.; Jiang, M.-M.; Hu, B.; Zhou, K.-Q.; Guo, W.; Xu, Y.; Zhong, Y.; Zhou, X.-R.; et al. Dissecting spatial
heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma. Nat. Commun.
2021, 12, 1–14. [CrossRef]
22. Ogle, L.F.; Orr, J.G.; Willoughby, C.; Hutton, C.; McPherson, S.; Plummer, R.; Boddy, A.; Curtin, N.; Jamieson, D.; Reeves, H.L.
Imagestream detection and characterisation of circulating tumour cells—A liquid biopsy for hepatocellular carcinoma? J. Hepatol.
2016, 65, 305–313. [CrossRef]
23. Li, J.; Shi, L.; Zhang, X.; Sun, B.; Yang, Y.; Ge, N.; Liu, H.; Yang, X.; Chen, L.; Qian, H.; et al. pERK/pAkt phenotyping in
circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncotarget 2015,
7, 2646–2659. [CrossRef]
24. Zhou, Y.; Wang, B.; Wu, J.; Zhang, C.; Zhou, Y.; Yang, X.; Zhou, J.; Guo, W.; Fan, J. Association of preoperative EpCAM Circulating
Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection.
BMC Cancer 2016, 16, 506. [CrossRef] [PubMed]
25. Guo, W.; Sun, Y.-F.; Shen, M.-N.; Ma, X.-L.; Wu, J.; Zhang, C.-Y.; Zhou, Y.; Xu, Y.; Hu, B.; Zhang, M.; et al. Circulating Tumor Cells
with Stem-Like Phenotypes for Diagnosis, Prognosis, and Therapeutic Response Evaluation in Hepatocellular Carcinoma. Clin.
Cancer Res. 2018, 24, 2203–2213. [CrossRef] [PubMed]
26. Guo, W.; Yang, X.-R.; Sun, Y.-F.; Shen, M.-N.; Ma, X.-L.; Wu, J.; Zhang, C.-Y.; Zhou, Y.; Xu, Y.; Hu, B.; et al. Clinical Significance
of EpCAM mRNA-Positive Circulating Tumor Cells in Hepatocellular Carcinoma by an Optimized Negative Enrichment and
qRT-PCR–Based Platform. Clin. Cancer Res. 2014, 20, 4794–4805. [CrossRef]
27. He, Y.Z.; He, K.; Huang, R.Q.; Wang, Z.L.; Ye, S.W.; Liu, L.W.; Luo, Q.J.; Hu, Z.M. Preoperative evaluation and prediction of
clinical scores for hepatocellular carcinoma microvascular invasion: A single-center retrospective analysis. Ann. Hepatol. 2020, 19,
654–661. [CrossRef] [PubMed]
28. He, Y.Z.; He, K.; Huang, R.Q.; Liu, L.W.; Ye, S.W.; Qian, J.L.; Peng, P.; Luo, Q.J.; Wang, Z.L.; Hu, Z.M. A clinical scoring system for
predicting tumor recurrence after percutaneous radiofrequency ablation for 3 cm or less hepatocellular carcinoma. Sci. Rep. 2021,
11, 1–14. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 13073 14 of 19
29. Chen, Z.; Lin, X.; Chen, C.; Chen, Y.; Zhao, Q.; Wu, L.; Wang, D.; Ma, Y.; Ju, W.; Chen, M.; et al. Analysis of preoperative
circulating tumor cells for recurrence in patients with hepatocellular carcinoma after liver transplantation. Ann. Transl. Med. 2020,
8, 1067. [CrossRef]
30. Xue, F.; Shi, S.; Zhang, Z.; Xu, C.; Zheng, J.; Qin, T.; Qian, Z.; Zhao, X.; Tong, Y.; Xia, L.; et al. Application of a novel liquid biopsy
in patients with hepatocellular carcinoma undergoing liver transplantation. Oncol. Lett. 2018, 15, 5481–5488. [CrossRef]
31. Deng, J.; Chen, W.; Wu, X.; Zhou, Y.; Li, J. Evaluating the predictive power of circulating tumor cells for the prognosis of
transarterial chemoembolization treatment on patients with advanced hepatocellular carcinoma. Medicine 2021, 100, e24060.
[CrossRef]
32. Wu, X.; Yang, C.; Yu, H.; Cao, F.; Shan, Y.; Zhao, W. The predictive values of serum dickkopf-1 and circulating tumor cells in
evaluating the efficacy of transcatheter arterial chemoembolization treatment on hepatocellular carcinoma. Medicine 2019, 98,
e16579. [CrossRef]
33. Liu, Y.-K.; Hu, B.-S.; Li, Z.-L.; He, X.; Li, Y.; Lu, L.-G. An improved strategy to detect the epithelial-mesenchymal transition
process in circulating tumor cells in hepatocellular carcinoma patients. Hepatol. Int. 2016, 10, 640–646. [CrossRef]
34. Wang, S.; Zheng, Y.; Liu, J.; Huo, F.; Zhou, J. Analysis of circulating tumor cells in patients with hepatocellular carcinoma
recurrence following liver transplantation. J. Investig. Med. 2018, 66, 1–6. [CrossRef] [PubMed]
35. Morris, K.L.; Tugwood, J.D.; Khoja, L.; Lancashire, M.; Sloane, R.S.; Burt, D.; Shenjere, P.; Zhou, C.; Hodgson, C.; Ohtomo, T.; et al.
Circulating biomarkers in hepatocellular carcinoma. Cancer Chemother. Pharmacol. 2014, 74, 323–332. [CrossRef]
36. Ou, H.; Huang, Y.; Xiang, L.; Chen, Z.; Fang, Y.; Lin, Y.; Cui, Z.; Yu, S.; Li, X.; Yang, D. Circulating Tumor Cell Phenotype Indicates
Poor Survival and Recurrence After Surgery for Hepatocellular Carcinoma. Dig. Dis. Sci. 2018, 63, 2373–2380. [CrossRef]
[PubMed]
37. Ye, X.; Li, G.; Han, C.; Han, Q.; Shang, L.; Su, H.; Han, B.; Gong, Y.; Lu, G.; Peng, T. Circulating tumor cells as a potential
biomarker for postoperative clinical outcome in HBV-related hepatocellular carcinoma. Cancer Manag. Res. 2018, 10, 5639–5647.
[CrossRef]
38. Takahashi, K.; Ofuji, K.; Hiramatsu, K.; Nosaka, T.; Naito, T.; Matsuda, H.; Endo, K.; Higuchi, M.; Ohtani, M.; Nemoto, T.; et al.
Circulating tumor cells detected with a microcavity array predict clinical outcome in hepatocellular carcinoma. Cancer Med. 2021,
10, 2300–2309. [CrossRef] [PubMed]
39. Chen, Y.; Li, S.; Li, W.; Yang, R.; Zhang, X.; Ye, Y.; Yu, J.; Ye, L.; Tang, W. Circulating tumor cells undergoing EMT are poorly
correlated with clinical stages or predictive of recurrence in hepatocellular carcinoma. Sci. Rep. 2019, 9, 7084. [CrossRef]
40. Qi, L.-N.; Xiang, B.-D.; Wu, F.-X.; Ye, J.-Z.; Zhong, J.-H.; Wang, Y.-Y.; Chen, Y.-Y.; Chen, Z.-S.; Ma, L.; Chen, J.; et al. Circulating
Tumor Cells Undergoing EMT Provide a Metric for Diagnosis and Prognosis of Patients with Hepatocellular Carcinoma. Cancer
Res. 2018, 78, 4731–4744. [CrossRef] [PubMed]
41. Luo, Q.; Wang, C.; Peng, B.; Pu, X.; Cai, L.; Liao, H.; Chen, K.; Zhang, C.; Cheng, Y.; Pan, M. Circulating Tumor-Cell-Associated
White Blood Cell Clusters in Peripheral Blood Indicate Poor Prognosis in Patients With Hepatocellular Carcinoma. Front. Oncol.
2020, 10, 1758. [CrossRef] [PubMed]
42. Wang, C.; Luo, Q.; Huang, W.; Zhang, C.; Liao, H.; Chen, K.; Pan, M. Correlation Between Circulating Tumor Cell DNA Genomic
Alterations and Mesenchymal CTCs or CTC-Associated White Blood Cell Clusters in Hepatocellular Carcinoma. Front. Oncol.
2021, 11, 686365. [CrossRef]
43. Wang, Z.; Luo, L.; Cheng, Y.; Ze-Sheng, J.; Peng, B.; Gao, Y.; Jiang, Z.-S.; Pan, M. Correlation Between Postoperative Early
Recurrence of Hepatocellular Carcinoma and Mesenchymal Circulating Tumor Cells in Peripheral Blood. J. Gastrointest. Surg.
2018, 22, 633–639. [CrossRef]
44. Cheng, Y.; Luo, L.; Zhang, J.; Zhou, M.; Tang, Y.; He, G.; Lu, Y.; Wang, Z.; Pan, M. Diagnostic Value of Different Phenotype
Circulating Tumor Cells in Hepatocellular Carcinoma. J. Gastrointest. Surg. 2019, 23, 2354–2361. [CrossRef]
45. Chen, J.; Cao, S.-W.; Cai, Z.; Zheng, L.; Wang, Q. Epithelial-mesenchymal transition phenotypes of circulating tumor cells correlate
with the clinical stages and cancer metastasis in hepatocellular carcinoma patients. Cancer Biomarkers 2017, 20, 487–498. [CrossRef]
46. Li, Y.; Huang, N.; Wang, C.; Ma, H.; Zhou, M.; Lin, L.; Huang, Z.; Sun, L.; Shi, M.; Liao, W. Impact of liver tumor percutaneous
radiofrequency ablation on circulating tumor cells. Oncol. Lett. 2018, 16, 2839–2850. [CrossRef]
47. Vona, G.; Sabile, A.; Louha, M.; Sitruk, V.; Romana, S.P.; Schütze, K.; Capron, F.; Franco, D.; Pazzagli, M.; Vekemans, M.; et al.
Isolation by Size of Epithelial Tumor Cells: A New Method for the Immunomorphological and Molecular Characterization of
Circulating Tumor Cells. Am. J. Pathol. 2000, 156, 57–63. [CrossRef]
48. Qi, L.-N.; Ma, L.; Chen, Y.-Y.; Chen, Z.-S.; Zhong, J.-H.; Gong, W.-F.; Lu, Y.; Xiang, B.-D.; Li, L.-Q. Outcomes of anatomical versus
non-anatomical resection for hepatocellular carcinoma according to circulating tumour-cell status. Ann. Med. 2020, 52, 21–31.
[CrossRef] [PubMed]
49. Zhou, J.; Zhang, Z.; Zhou, H.; Leng, C.; Hou, B.; Zhou, C.; Hu, X.; Wang, J.; Chen, X. Preoperative circulating tumor cells to
predict microvascular invasion and dynamical detection indicate the prognosis of hepatocellular carcinoma. BMC Cancer 2020, 20,
1047. [CrossRef]
50. Yin, L.-C.; Luo, Z.-C.; Gao, Y.-X.; Li, Y.; Peng, Q.; Gao, Y. Twist Expression in Circulating Hepatocellular Carcinoma Cells Predicts
Metastasis and Prognoses. BioMed Res. Int. 2018, 2018, 3789613. [CrossRef]
51. Bankó, P.; Lee, S.Y.; Nagygyörgy, V.; Zrínyi, M.; Chae, C.H.; Cho, D.H.; Telekes, A. Technologies for circulating tumor cell
separation from whole blood. J. Hematol. Oncol. 2019, 12, 1–20. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2021, 22, 13073 15 of 19
52. Court, C.M.; Hou, S.; Winograd, P.; Segel, N.H.; Li, Q.W.; Zhu, Y.; Sadeghi, S.; Finn, R.S.; Ganapathy, E.; Song, M.; et al. A novel
multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma. Liver Transplant. 2018, 24,
946–960. [CrossRef]
53. Yu, J.-J.; Xiao, W.; Dong, S.-L.; Liang, H.-F.; Zhang, Z.-W.; Zhang, B.-X.; Huang, Z.-Y.; Chen, Y.-F.; Zhang, W.-G.; Luo, H.-P.; et al.
Effect of surgical liver resection on circulating tumor cells in patients with hepatocellular carcinoma. BMC Cancer 2018, 18, 835.
[CrossRef]
54. Shen, J.; Wang, W.-S.; Zhu, X.-L.; Ni, C.-F. High Epithelial Cell Adhesion Molecule–Positive Circulating Tumor Cell Count Predicts
Poor Survival of Patients with Unresectable Hepatocellular Carcinoma Treated with Transcatheter Arterial Chemoembolization. J.
Vasc. Interv. Radiol. 2018, 29, 1678–1684. [CrossRef]
55. Von Felden, J.; Schulze, K.; Krech, T.; Ewald, F.; Nashan, B.; Pantel, K.; Lohse, A.W.; Riethdorf, S.; Wege, H. Circulating tumor
cells as liquid biomarker for high HCC recurrence risk after curative liver resection. Oncotarget 2017, 8, 89978–89987. [CrossRef]
56. Sun, Y.; Wang, P.; Cheng, J.; Gong, Z.; Huang, A.; Zhou, K.; Hu, B.; Gao, P.; Cao, Y.; Qiu, S.; et al. Postoperative circulating
tumor cells: An early predictor of extrahepatic metastases in patients with hepatocellular carcinoma undergoing curative surgical
resection. Cancer Cytopathol. 2020, 128, 733–745. [CrossRef]
57. Ge, Z.; Helmijr, J.C.; Jansen, M.P.; Boor, P.P.; Noordam, L.; Peppelenbosch, M.; Kwekkeboom, J.; Kraan, J.; Sprengers, D. Detection
of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma.
Transl. Oncol. 2021, 14, 101073. [CrossRef]
58. Schulze, K.; Gasch, C.; Staufer, K.; Nashan, B.; Lohse, A.W.; Pantel, K.; Riethdorf, S.; Wege, H. Presence of EpCAM-positive
circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma.
Int. J. Cancer 2013, 133, 2165–2171. [CrossRef]
59. Kelley, R.K.; Magbanua, M.J.M.; Butler, T.M.; Collisson, E.A.; Hwang, J.; Sidiropoulos, N.; Evason, K.; McWhirter, R.M.; Hameed,
B.; Wayne, E.M.; et al. Circulating tumor cells in hepatocellular carcinoma: A pilot study of detection, enumeration, and
next-generation sequencing in cases and controls. BMC Cancer 2015, 15, 206. [CrossRef]
60. Sun, Y.-F.; Xu, Y.; Yang, X.-R.; Guo, W.; Zhang, X.; Qiu, S.-J.; Shi, R.-Y.; Hu, B.; Zhou, J.; Fan, J. Circulating stem cell-like
epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection.
Hepatology 2013, 57, 1458–1468. [CrossRef]
61. Wang, P.; Sun, Y.; Zhou, K.; Cheng, J.; Hu, B.; Guo, W.; Yin, Y.; Huang, J.; Zhou, J.; Fan, J.; et al. Circulating tumor cells are
an indicator for the administration of adjuvant transarterial chemoembolization in hepatocellular carcinoma: A single-center,
retrospective, propensity-matched study. Clin. Transl. Med. 2020, 10, e137. [CrossRef] [PubMed]
62. Zhou, K.-Q.; Sun, Y.-F.; Cheng, J.-W.; Du, M.; Ji, Y.; Wang, P.-X.; Hu, B.; Guo, W.; Gao, Y.; Yin, Y.; et al. Effect of surgical margin
on recurrence based on preoperative circulating tumor cell status in hepatocellular carcinoma. EBioMedicine 2020, 62, 103107.
[CrossRef]
63. Fischer, J.; Niederacher, D.; Topp, S.A.; Honisch, E.; Schumacher, S.; Schmitz, N.; Fohrding, L.Z.; Vay, C.; Hoffmann, I.; Kasprowicz,
N.S.; et al. Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. Proc.
Natl. Acad. Sci. USA 2013, 110, 16580–16585. [CrossRef]
64. Sánchez-Lorencio, M.; Ramirez, P.; Saenz, L.; Sánchez, M.D.R.G.; De La Orden, V.; Mediero-Valeros, B.; Veganzones, S.; Baroja-
Mazo, A.; Nuin, B.C.R.; Gonzalez, M.; et al. Comparison of Two Types of Liquid Biopsies in Patients With Hepatocellular
Carcinoma Awaiting Orthotopic Liver Transplantation. Transplant. Proc. 2015, 47, 2639–2642. [CrossRef]
65. Tsuchiya, N. Biomarkers for the early diagnosis of hepatocellular carcinoma. World J. Gastroenterol. 2015, 21, 10573–10583.
[CrossRef]
66. Rodríguez-Perálvarez, M.; Luong, T.V.; Andreana, L.; Meyer, T.; Dhillon, A.P.; Burroughs, A.K. A Systematic Review of
Microvascular Invasion in Hepatocellular Carcinoma: Diagnostic and Prognostic Variability. Ann. Surg. Oncol. 2012, 20, 325–339.
[CrossRef]
67. Hamaoka, M.; Kobayashi, T.; Tanaka, Y.; Mashima, H.; Ohdan, H. Clinical significance of glypican-3-positive circulating tumor
cells of hepatocellular carcinoma patients: A prospective study. PLoS ONE 2019, 14, e0217586. [CrossRef]
68. Spiess, M. The asialoglycoprotein receptor: A model for endocytic transport receptors. Biochemistry 1990, 29, 10009–10018.
[CrossRef]
69. Fan, Z.; Van De Rijn, M.; Montgomery, K.; Rouse, R.V. Hep Par 1 Antibody Stain for the Differential Diagnosis of Hepatocellular
Carcinoma: 676 Tumors Tested Using Tissue Microarrays and Conventional Tissue Sections. Mod. Pathol. 2003, 16, 137–144.
[CrossRef]
70. Xu, W.; Cao, L.; Chen, L.; Li, J.; Zhang, X.-F.; Qian, H.-H.; Kang, X.-Y.; Zhang, Y.; Liao, J.; Shi, L.-H.; et al. Isolation of Circulating
Tumor Cells in Patients with Hepatocellular Carcinoma Using a Novel Cell Separation Strategy. Clin. Cancer Res. 2011, 17,
3783–3793. [CrossRef]
71. Li, J.; Chen, L.; Zhang, X.; Zhang, Y.; Liu, H.; Sun, B.; Zhao, L.; Ge, N.; Qian, H.; Yang, Y.; et al. Detection of Circulating Tumor
Cells in Hepatocellular Carcinoma Using Antibodies against Asialoglycoprotein Receptor, Carbamoyl Phosphate Synthetase 1
and Pan-Cytokeratin. PLoS ONE 2014, 9, e96185. [CrossRef] [PubMed]
72. Zhang, Y.; Zhang, X.; Zhang, J.; Sun, B.; Zheng, L.; Li, J.; Liu, S.; Sui, G.; Yin, Z. Microfluidic chip for isolation of viable circulating
tumor cells of hepatocellular carcinoma for their culture and drug sensitivity assay. Cancer Biol. Ther. 2016, 17, 1177–1187.
[CrossRef] [PubMed]
Int. J. Mol. Sci. 2021, 22, 13073 16 of 19
73. Wan, S.; Kim, T.H.; Smith, K.J.; Delaney, R.; Park, G.-S.; Guo, H.; Lin, E.; Plegue, T.; Kuo, N.; Steffes, J.; et al. New Labyrinth
Microfluidic Device Detects Circulating Tumor Cells Expressing Cancer Stem Cell Marker and Circulating Tumor Microemboli in
Hepatocellular Carcinoma. Sci. Rep. 2019, 9, 1–11. [CrossRef] [PubMed]
74. Mu, H. Identification of biomarkers for hepatocellular carcinoma by semiquantitative immunocytochemistry. World J. Gastroenterol.
2014, 20, 5826–5838. [CrossRef] [PubMed]
75. Gires, O.; Stoecklein, N.H. Dynamic EpCAM expression on circulating and disseminating tumor cells: Causes and consequences.
Cell. Mol. Life Sci. 2014, 71, 4393–4402. [CrossRef] [PubMed]
76. Ramirez, P.; Sáenz, L.; Cascales-Campos, P.; Sánchez, M.G.; Llàcer-Millán, E.; Sánchez-Lorencio, M.; Díaz-Rubio, E.; De La Orden,
V.; Mediero-Valeros, B.; Navarro, J.; et al. Oncological Evaluation by Positron-emission Tomography, Circulating Tumor Cells and
Alpha Fetoprotein in Patients with Hepatocellular Carcinoma on the Waiting List for Liver Transplantation. Transplant. Proc.
2016, 48, 2962–2965. [CrossRef] [PubMed]
77. De Wit, S.; Manicone, M.; Rossi, E.; Lampignano, R.; Yang, L.; Zill, B.; Rengel-Puertas, A.; Ouhlen, M.; Crespo, M.; Berghuis,
A.M.S.; et al. EpCAMhigh and EpCAMlow circulating tumor cells in metastatic prostate and breast cancer patients. Oncotarget
2018, 9, 35705–35716. [CrossRef]
78. Nicolazzo, C.; Gradilone, A.; Loreni, F.; Raimondi, C.; Gazzaniga, P. EpCAMlow Circulating Tumor Cells: Gold in the Waste. Dis.
Markers 2019, 2019, 1–5. [CrossRef] [PubMed]
79. Giannelli, G.; Koudelkova, P.; Dituri, F.; Mikulits, W. Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J.
Hepatol. 2016, 65, 798–808. [CrossRef]
80. Terris, B.; Cavard, C.; Perret, C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J. Hepatol. 2010, 52,
280–281. [CrossRef]
81. Yamashita, T.; Ji, J.; Budhu, A.; Forgues, M.; Yang, W.; Wang, H.; Jia, H.; Ye, Q.; Qin, L.; Wauthier, E.; et al. EpCAM-Positive
Hepatocellular Carcinoma Cells Are Tumor-Initiating Cells With Stem/Progenitor Cell Features. Gastroenterology 2009, 136,
1012–1024. [CrossRef]
82. Zhang, Y.; Weinberg, R.A. Epithelial-to-mesenchymal transition in cancer: Complexity and opportunities. Front. Med. 2018, 12,
361–373. [CrossRef] [PubMed]
83. Ayob, A.Z.; Ramasamy, T.S. Cancer stem cells as key drivers of tumour progression. J. Biomed. Sci. 2018, 25, 20. [CrossRef]
[PubMed]
84. Sun, Y.-F.; Guo, W.; Xu, Y.; Shi, Y.-H.; Gong, Z.-J.; Ji, Y.; Du, M.; Zhang, X.; Hu, B.; Huang, A.; et al. Circulating Tumor Cells
from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical
Significance in Hepatocellular Carcinoma. Clin. Cancer Res. 2017, 24, 547–559. [CrossRef] [PubMed]
85. Sha, Y.; Haensel, D.; Gutierrez, G.; Du, H.; Dai, X.; Nie, Q. Intermediate cell states in epithelial-to-mesenchymal transition. Phys.
Biol. 2019, 16, 021001. [CrossRef] [PubMed]
86. Li, Y.-M.; Xu, S.-C.; Li, J.; Han, K.-Q.; Pi, H.-F.; Zheng, L.; Zuo, G.-H.; Huang, X.-B.; Li, H.-Y.; Zhao, H.-Z.; et al. Epithelial–
mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of
disease. Cell Death Dis. 2013, 4, e831. [CrossRef] [PubMed]
87. Hong, Y.; Fang, F.; Zhang, Q. Circulating tumor cell clusters: What we know and what we expect (Review). Int. J. Oncol. 2016, 49,
2206–2216. [CrossRef]
88. Duda, D.G.; Duyverman, A.M.M.J.; Kohno, M.; Snuderl, M.; Steller, E.J.A.; Fukumura, D.; Jain, R.K. Malignant cells facilitate lung
metastasis by bringing their own soil. Proc. Natl. Acad. Sci. USA 2010, 107, 21677–21682. [CrossRef]
89. Tayoun, T.; Faugeroux, V.; Oulhen, M.; Aberlenc, A.; Pawlikowska, P.; Farace, F. CTC-Derived Models: A Window into the
Seeding Capacity of Circulating Tumor Cells (CTCs). Cells 2019, 8, 1145. [CrossRef] [PubMed]
90. Lara-Pezzi, E.; Serrador, J.M.; Montoya, M.C.; Zamora, D.; Yáñez-Mó, M.; Carretero, M.; Furthmayr, H.; Sánchez-Madrid, F.;
López-Cabrera, M. The hepatitis B virus X protein (HBx) induces a migratory phenotype in a CD44-dependent manner: Possible
role of HBx in invasion and metastasis. Hepatology 2001, 33, 1270–1281. [CrossRef]
91. Zhu, Z.; Hao, X.; Yan, M.; Yao, M.; Ge, C.; Gu, J.; Li, J. Cancer stem/progenitor cells are highly enriched in CD133+CD44+population
in hepatocellular carcinoma. Int. J. Cancer 2009, 126, 2067–2078. [CrossRef]
92. Zahran, A.M.; Abdel-Rahim, M.; Refaat, A.; Sayed, M.; Othman, M.M.; Khalak, L.M.R.; Hetta, H.F. Circulating hematopoietic
stem cells, endothelial progenitor cells and cancer stem cells in hepatocellular carcinoma patients: Contribution to diagnosis and
prognosis. Acta Oncol. 2020, 59, 33–39. [CrossRef] [PubMed]
93. Yang, Z.F.; Ho, D.W.; Ng, M.N.; Lau, C.K.; Yu, W.C.; Ngai, P.; Chu, P.W.; Lam, C.T.; Poon, R.T.; Fan, S.T. Significance of CD90+
Cancer Stem Cells in Human Liver Cancer. Cancer Cell 2008, 13, 153–166. [CrossRef] [PubMed]
94. Zhu, L.; Zhang, W.; Wang, J.; Liu, R. Evidence of CD90+CXCR4+ cells as circulating tumor stem cells in hepatocellular carcinoma.
Tumor Biol. 2015, 36, 5353–5360. [CrossRef] [PubMed]
95. Govaere, O.; Komuta, M.; Berkers, J.; Spee, B.; Janssen, C.; de Luca, F.; Katoonizadeh, A.; Wouters, J.; van Kempen, L.C.; Durnez,
A.; et al. Keratin 19: A key role player in the invasion of human hepatocellular carcinomas. Gut 2014, 63, 674–685. [CrossRef]
[PubMed]
96. Hwang, H.S.; Yoo, J.E.; Han, D.H.; Choi, J.S.; Lee, J.G.; Joo, D.J.; Kim, M.S.; Kim, S.I.; Choi, G.H.; Park, A.Y.N. Circulating Cancer
Stem Cells Expressing EpCAM/CD90 in Hepatocellular Carcinoma: A Pilot Study for Predicting Tumor Recurrence after Living
Donor Liver Transplantation. Gut Liver 2021. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 13073 17 of 19
97. Liu, S.; Li, N.; Yu, X.; Xiao, X.; Cheng, K.; Hu, J.; Wang, J.; Zhang, D.; Cheng, S.; Liu, S. Expression of Intercellular Adhesion
Molecule 1 by Hepatocellular Carcinoma Stem Cells and Circulating Tumor Cells. Gastroenterology 2013, 144, 1031–1041. [CrossRef]
[PubMed]
98. Amado, V.; González-Rubio, S.; Zamora, J.; Alejandre, R.; Espejo-Cruz, M.; Linares, C.; Sánchez-Frías, M.; García-Jurado, G.;
Montero, J.; Ciria, R.; et al. Clearance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Surgical
Resection or Liver Transplantation. Cancers 2021, 13, 2476. [CrossRef]
99. Hanahan, D.; Weinberg, R.A. Hallmarks of Cancer: The Next Generation. Cell 2011, 144, 646–674. [CrossRef]
100. Rodríguez-Perálvarez, M.; Tsochatzis, E.; Naveas, M.C.; Pieri, G.; García-Caparrós, C.; O’Beirne, J.; Poyato-González, A.; Ferrín,
G.; Montero-Álvarez, J.L.; Patch, D.; et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents
recurrence of hepatocellular carcinoma. J. Hepatol. 2013, 59, 1193–1199. [CrossRef] [PubMed]
101. Toso, C.; Mentha, G.; Majno, P. Liver Transplantation for Hepatocellular Carcinoma: Five Steps to Prevent Recurrence. Arab.
Archaeol. Epigr. 2011, 11, 2031–2035. [CrossRef]
102. Wang, J.-H.; Fang, Z.-T.; Wang, G.Z.; Zhang, W.; Qu, X.-D.; Liu, R.; Qian, S.; Zhu, L.; Zhou, B. Transcatheter arterial embolization
promotes liver tumor metastasis by increasing the population of circulating tumor cells. OncoTargets Ther. 2013, 6, 1563–1572.
[CrossRef]
103. Vogl, T.J.; Riegelbauer, L.J.; Oppermann, E.; Kostantin, M.; Ackermann, H.; Trzmiel, A.; Stein, S.; Eichler, K.; Zharov, V.P.; Roy, D.;
et al. Early dynamic changes in circulating tumor cells and prognostic relevance following interventional radiological treatments
in patients with hepatocellular carcinoma. PLoS ONE 2021, 16, e0246527. [CrossRef]
104. Fang, Z.-T.; Wang, J.-H.; Zhang, W.; Wang, G.Z.; Yang, G.-W.; Qu, X.-D.; Liu, R.; Qian, S.; Zhu, L.; Zhou, B.; et al. Circulating
tumor cells in the central and peripheral venous compartment—Assessing hematogenous dissemination after transarterial
chemoembolization of hepatocellular carcinoma. OncoTargets Ther. 2014, 7, 1311–1318. [CrossRef] [PubMed]
105. Yan, J.; Fan, Z.; Wu, X.; Xu, M.; Jiang, J.; Tan, C.; Wu, W.; Wei, X.; Zhou, J. Circulating tumor cells are correlated with disease
progression and treatment response in an orthotopic hepatocellular carcinoma model. Cytom. Part A 2015, 87, 1020–1028.
[CrossRef] [PubMed]
106. Von Felden, J.; Craig, A.J.; Garcia-Lezana, T.; Labgaa, I.; Haber, P.K.; D’Avola, D.; Asgharpour, A.; Dieterich, D.; Bonaccorso,
A.; Torres-Martin, M.; et al. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced
hepatocellular carcinoma. Oncogene 2021, 40, 140–151. [CrossRef] [PubMed]
107. Pizon, M.; Schott, D.; Pachmann, U.; Pachmann, K. The number of tumorspheres cultured from peripheral blood is a predictor for
presence of metastasis in patients with breast cancer. Oncotarget 2016, 7, 48143–48154. [CrossRef] [PubMed]
108. Yu, M.; Bardia, A.; Aceto, N.; Bersani, F.; Madden, M.W.; Donaldson, M.C.; Desai, R.; Zhu, H.; Comaills, V.; Zheng, Z.; et al.
Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 2014, 345, 216–220.
[CrossRef]
109. Cao, L.; Zhou, Y.; Zhai, B.; Liao, J.; Xu, W.; Zhang, R.; Li, J.; Zhang, Y.; Chen, L.; Qian, H.; et al. Sphere-forming cell subpopulations
with cancer stem cell properties in human hepatoma cell lines. BMC Gastroenterol. 2011, 11, 71. [CrossRef] [PubMed]
110. Huo, Y.; Chen, W.S.; Lee, J.; Feng, G.-S.; Newton, I.G. Stress Conditions Induced by Locoregional Therapies Stimulate Enrichment
and Proliferation of Liver Cancer Stem Cells. J. Vasc. Interv. Radiol. 2019, 30, 2016–2025. [CrossRef] [PubMed]
111. Hernández, L.E.C.; Eslami-S, Z.; Alix-Panabières, C. Circulating tumor cell as the functional aspect of liquid biopsy to understand
the metastatic cascade in solid cancer. Mol. Asp. Med. 2020, 72, 100816. [CrossRef] [PubMed]
112. Grillet, F.; Bayet, E.; Villeronce, O.; Zappia, L.; Lagerqvist, E.L.; Lunke, S.; Charafe-Jauffret, E.; Pham, K.; Molck, C.; Rolland,
N.; et al. Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks inex vivoculture. Gut 2017,
66, 1802–1810. [CrossRef] [PubMed]
113. Luo, Y.T.; Cheng, J.; Feng, X.; He, S.J.; Wang, Y.W.; Huang, Q. The viable circulating tumor cells with cancer stem cells feature,
where is the way out? J. Exp. Clin. Cancer Res. 2018, 37, 1–13. [CrossRef]
114. Zhao, P.; Zhou, W.; Liu, C.; Zhang, H.; Cheng, Z.; Wu, W.; Liu, K.; Hu, H.; Zhong, C.; Zhang, Y.; et al. Establishment and
Characterization of a CTC Cell Line from Peripheral Blood of Breast Cancer Patient. J. Cancer 2019, 10, 6095–6104. [CrossRef]
115. Que, Z.; Luo, B.; Zhou, Z.; Dong, C.; Jiang, Y.; Wang, L.; Shi, Q.; Tian, J. Establishment and characterization of a patient-derived
circulating lung tumor cell line in vitro and in vivo. Cancer Cell Int. 2019, 19, 21. [CrossRef] [PubMed]
116. Hu, C.-L.; Zhang, Y.-J.; Zhang, X.-F.; Fei, X.; Zhang, H.; Li, C.-G.; Sun, B. 3D Culture of Circulating Tumor Cells for Evaluating
Early Recurrence and Metastasis in Patients with Hepatocellular Carcinoma. OncoTargets Ther. 2021, 14, 2673–2688. [CrossRef]
[PubMed]
117. Abdel-Salam, I.M.; Awadein, N.E.-S.; Ashour, M. Cytotoxicity of Luffa cylindrica (L.) M. Roem extract against circulating cancer
stem cells in hepatocellular carcinoma. J. Ethnopharmacol. 2019, 229, 89–96. [CrossRef]
118. Wu, L.-J.; Pan, Y.-D.; Pei, X.-Y.; Chen, H.; Nguyen, S.; Kashyap, A.; Liu, J.; Wu, J. Capturing circulating tumor cells of hepatocellular
carcinoma. Cancer Lett. 2012, 326, 17–22. [CrossRef]
119. Yoshikawa, N.; Saito, Y.; Manabe, H.; Nakaoka, T.; Uchida, R.; Furukawa, R.; Muramatsu, T.; Sugiyama, Y.; Kimura, M.; Saito, H.
Glucose Depletion Enhances the Stem Cell Phenotype and Gemcitabine Resistance of Cholangiocarcinoma Organoids through
AKT Phosphorylation and Reactive Oxygen Species. Cancers 2019, 11, 1993. [CrossRef]
120. Buffa, F.M.; Carmeliet, P.; Giaccia, A.J.; Harris, A.L.; Imtiyaz, H.Z.; Johnson, R.S.; Johnsson, A.S.; Li, Z. Diverse Effects of Hypoxia on
Tumor Progression; Springer: Berlin/Heidelberg, Germany, 2010; Volume 345, ISBN 978-3-642-13328-2.
Int. J. Mol. Sci. 2021, 22, 13073 18 of 19
121. Cosse, J.-P. Tumour Hypoxia Affects the Responsiveness of Cancer Cells to Chemotherapy and Promotes Cancer Progression.
Anti-Cancer Agents Med. Chem. 2008, 8, 790–797. [CrossRef] [PubMed]
122. Rhee, H.; Nahm, J.H.; Kim, H.; Choi, G.H.; Yoo, J.E.; Lee, H.S.; Koh, M.J.; Park, Y.N. Poor outcome of hepatocellular carcinoma
with stemness marker under hypoxia: Resistance to transarterial chemoembolization. Mod. Pathol. 2016, 29, 1038–1049. [CrossRef]
123. Cayrefourcq, L.; Mazard, T.; Joosse, S.; Solassol, J.; Ramos, J.; Assenat, E.; Schumacher, U.; Costes, V.; Maudelonde, T.; Pantel,
K.; et al. Establishment and Characterization of a Cell Line from Human Circulating Colon Cancer Cells. Cancer Res. 2015, 75,
892–901. [CrossRef]
124. Wang, Z.; Wu, W.; Wang, Z.; Tang, Y.; Deng, Y.; Xu, L.; Tian, J.; Shi, Q. Ex vivo expansion of circulating lung tumor cells based on
one-step microfluidics-based immunomagnetic isolation. Analyst 2016, 141, 3621–3625. [CrossRef]
125. Brungs, D.; Minaei, E.; Piper, A.-K.; Perry, J.; Splitt, A.; Carolan, M.; Ryan, S.; Wu, X.J.; Corde, S.; Tehei, M.; et al. Establish-
ment of novel long-term cultures from EpCAM positive and negative circulating tumour cells from patients with metastatic
gastroesophageal cancer. Sci. Rep. 2020, 10, 1–13. [CrossRef]
126. Kim, T.H.; Wang, Y.; Oliver, C.R.; Thamm, D.; Cooling, L.; Paoletti, C.; Smith, K.J.; Nagrath, S.; Hayes, D.F. A temporary indwelling
intravascular aphaeretic system for in vivo enrichment of circulating tumor cells. Nat. Commun. 2019, 10, 1478. [CrossRef]
127. Saucedo-Zeni, N.; Mewes, S.; Niestroj, R.; Gasiorowski, L.; Murawa, D.; Nowaczyk, P.; Tomasi, T.; Weber, E.; Dworacki, G.;
Morgenthaler, N.G.; et al. A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer
patients using a functionalized and structured medical wire. Int. J. Oncol. 2012, 41, 1241–1250. [CrossRef]
128. Wang, D.; Ge, C.; Liang, W.; Yang, Q.; Liu, Q.; Ma, W.; Shi, L.; Wu, H.; Zhang, Y.; Wu, Z.; et al. In Vivo Enrichment and Elimination
of Circulating Tumor Cells by Using a Black Phosphorus and Antibody Functionalized Intravenous Catheter. Adv. Sci. 2020, 7,
2000940. [CrossRef]
129. Winograd, P.; Hou, S.; Court, C.M.; Lee, Y.-T.; Chen, P.-J.; Zhu, Y.; Sadeghi, S.; Finn, R.S.; Teng, P.-C.; Wang, J.J.; et al. Hepatocellular
Carcinoma–Circulating Tumor Cells Expressing PD-L1 Are Prognostic and Potentially Associated With Response to Checkpoint
Inhibitors. Hepatol. Commun. 2020, 4, 1527–1540. [CrossRef] [PubMed]
130. Zhu, L.; Liu, R.; Zhang, W.; Qian, S.; Wang, J. Application of EGFR inhibitor reduces circulating tumor cells during transcatheter
arterial embolization. Clin. Transl. Oncol. 2017, 20, 639–646. [CrossRef] [PubMed]
131. Yang, Z.F.; Ngai, P.; Ho, D.W.; Yu, W.C.; Ng, M.N.; Lau, C.K.; Li, M.L.Y.; Tam, K.H.; Lam, C.T.; Poon, R.T.P.; et al. Identification of
local and circulating cancer stem cells in human liver cancer. Hepatology 2008, 47, 919–928. [CrossRef] [PubMed]
132. Lai, H.-C.; Yeh, C.-C.; Jeng, L.-B.; Huang, S.-F.; Liao, P.-Y.; Lei, F.-J.; Cheng, W.-C.; Hsu, C.-L.; Cai, X.; Chang, C.; et al. Androgen
receptor mitigates postoperative disease progression of hepatocellular carcinoma by suppressing CD90+ populations and cell
migration and by promoting anoikis in circulating tumor cells. Oncotarget 2016, 7, 46448–46465. [CrossRef]
133. Li, Y.; Xu, Y.; Gao, C.; Sun, Y.; Zhou, K.; Wang, P.; Cheng, J.; Guo, W.; Ya, C.; Fan, J.; et al. USP1 Maintains the Survival of Liver
Circulating Tumor Cells by Deubiquitinating and Stabilizing TBLR1. Front. Oncol. 2020, 10, 554809. [CrossRef]
134. Lee, D.; Na, J.; Ryu, J.; Kim, H.-J.; Nam, S.H.; Kang, M.; Jung, J.W.; Lee, M.-S.; Song, H.E.; Choi, J.; et al. Interaction of tetraspan(in)
TM4SF5 with CD44 promotes self-renewal and circulating capacities of hepatocarcinoma cells. Hepatology 2015, 61, 1978–1997.
[CrossRef]
135. Ogawa, T.; Tashiro, H.; Miyata, Y.; Ushitora, Y.; Fudaba, Y.; Kobayashi, T.; Arihiro, K.; Okajima, M.; Asahara, T. Rho-Associated
Kinase Inhibitor Reduces Tumor Recurrence After Liver Transplantation in a Rat Hepatoma Model. Arab. Archaeol. Epigr. 2007, 7,
347–355. [CrossRef]
136. Tang, Y.; Lu, Y.; Chen, Y.; Luo, L.; Cai, L.; Peng, B.; Huang, W.; Liao, H.; Zhao, L.; Pan, M. Pre-metastatic niche triggers
SDF-1/CXCR4 axis and promotes organ colonisation by hepatocellular circulating tumour cells via downregulation of Prrx1. J.
Exp. Clin. Cancer Res. 2019, 38, 1–13. [CrossRef]
137. Gentilini, A.; Rombouts, K.; Galastri, S.; Caligiuri, A.; Mingarelli, E.; Mello, T.; Marra, F.; Mantero, S.; Roncalli, M.; Inv-
ernizzi, P.; et al. Role of the stromal-derived factor-1 (SDF-1)–CXCR4 axis in the interaction between hepatic stellate cells and
cholangiocarcinoma. J. Hepatol. 2012, 57, 813–820. [CrossRef] [PubMed]
138. Matsusue, R.; Kubo, H.; Hisamori, S.; Okoshi, K.; Takagi, H.; Hida, K.; Nakano, K.; Itami, A.; Kawada, K.; Nagayama, S.; et al.
Hepatic Stellate Cells Promote Liver Metastasis of Colon Cancer Cells by the Action of SDF-1/CXCR4 Axis. Ann. Surg. Oncol.
2009, 16, 2645–2653. [CrossRef] [PubMed]
139. Goodwin, T.J.; Zhou, Y.; Musetti, S.N.; Liu, R.; Huang, L. Local and transient gene expression primes the liver to resist cancer
metastasis. Sci. Transl. Med. 2016, 8, 364ra153. [CrossRef] [PubMed]
140. Fang, T.; Lv, H.; Lv, G.; Li, T.; Wang, C.; Han, Q.; Yu, L.; Su, B.; Guo, L.; Huang, S.; et al. Tumor-derived exosomal miR-1247-3p
induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nat. Commun. 2018, 9, 191. [CrossRef]
141. Ji, J.; Zheng, X.; Forgues, M.; Yamashita, T.; Wauthier, E.L.; Reid, L.M.; Wen, X.; Song, Y.; Wei, J.S.; Khan, J.; et al. Identification of
microRNAs specific for epithelial cell adhesion molecule-positive tumor cells in hepatocellular carcinoma. Hepatology 2015, 62,
829–840. [CrossRef] [PubMed]
142. Fu, Q.; Zhang, Q.; Lou, Y.; Yang, J.; Nie, G.; Chen, Q.; Chen, Y.; Zhang, J.; Wang, J.; Wei, T.; et al. Primary tumor-derived exosomes
facilitate metastasis by regulating adhesion of circulating tumor cells via SMAD3 in liver cancer. Oncogene 2018, 37, 6105–6118.
[CrossRef]
143. Yang, M.; Zhang, C. The role of liver sinusoidal endothelial cells in cancer liver metastasis. Am. J. Cancer Res. 2021, 11, 1845–1860.
Int. J. Mol. Sci. 2021, 22, 13073 19 of 19
144. Zhuang, P.-Y.; Shen, J.; Zhu, X.-D.; Zhang, J.-B.; Tang, Z.-Y.; Qin, L.-X.; Sun, H.-C. Direct Transformation of Lung Microenvironment
by Interferon-α Treatment Counteracts Growth of Lung Metastasis of Hepatocellular Carcinoma. PLoS ONE 2013, 8, e58913.
[CrossRef]
145. Zhang, Y.; Shi, Z.-L.; Yang, X.; Yin, Z.-F. Targeting of circulating hepatocellular carcinoma cells to prevent postoperative recurrence
and metastasis. World J. Gastroenterol. 2014, 20, 142–147. [CrossRef] [PubMed]
146. Finn, R.S.; Qin, S.; Ikeda, M.; Galle, P.R.; Ducreux, M.; Kim, T.-Y.; Kudo, M.; Breder, V.; Merle, P.; Kaseb, A.O.; et al. Atezolizumab
plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N. Engl. J. Med. 2020, 382, 1894–1905. [CrossRef]
147. Chen, Y.; Chen, X.; Ding, X.; Wang, Y. Afatinib, an EGFR inhibitor, decreases EMT and tumorigenesis of Huh-7 cells by regulating
the ERK-VEGF/MMP9 signaling pathway. Mol. Med. Rep. 2019, 20, 3317–3325. [CrossRef]
148. Xue, F.; Takahara, T.; Yata, Y.; Xia, Q.; Nonome, K.; Shinno, E.; Kanayama, M.; Takahara, S.; Sugiyama, T. Blockade of RhoRho-
associated coiled coil-forming kinase signaling can prevent progression of hepatocellular carcinoma in matrix metalloproteinase-
dependent manner. Hepatol. Res. 2008, 38, 810–817. [CrossRef]
149. de Sousa, G.R.; Vieira, G.M.; das Chagas, P.F.; Pezuk, J.A.; Brassesco, M.S. Should we keep rocking? Portraits from targeting Rho
kinases in cancer. Pharmacol. Res. 2020, 160, 105093. [CrossRef] [PubMed]
150. Sun, J.-F.; Zhang, D.; Gao, C.-J.; Zhang, Y.-W.; Dai, Q.-S. Exosome-Mediated MiR-155 Transfer Contributes to Hepatocellular
Carcinoma Cell Proliferation by Targeting PTEN. Med. Sci. Monit. Basic Res. 2019, 25, 218–228. [CrossRef] [PubMed]
151. Chen, F.; Zhong, Z.; Tan, H.-Y.; Wang, N.; Feng, Y. The Significance of Circulating Tumor Cells in Patients with Hepatocellular
Carcinoma: Real-Time Monitoring and Moving Targets for Cancer Therapy. Cancers 2020, 12, 1734. [CrossRef]
152. Liu, Q.; Liao, Q.; Zhao, Y. Myeloid-derived suppressor cells (MDSC) facilitate distant metastasis of malignancies by shielding
circulating tumor cells (CTC) from immune surveillance. Med. Hypotheses 2016, 87, 34–39. [CrossRef] [PubMed]
153. Hamilton, G.; Rath, B.; Klameth, L.; Hochmair, M.J. Small cell lung cancer: Recruitment of macrophages by circulating tumor
cells. OncoImmunology 2016, 5, e1093277. [CrossRef] [PubMed]
154. Carambia, A.; Freund, B.; Schwinge, D.; Heine, M.; Laschtowitz, A.; Huber, S.; Wraith, D.C.; Korn, T.; Schramm, C.; Lohse,
A.W.; et al. TGF-β-dependent induction of CD4+CD25+Foxp3+ Tregs by liver sinusoidal endothelial cells. J. Hepatol. 2014, 61,
594–599. [CrossRef] [PubMed]
155. Serrels, A.; Lund, T.; Serrels, B.; Byron, A.; McPherson, R.C.; von Kriegsheim, A.; Gómez-Cuadrado, L.; Canel, M.; Muir, M.; Ring,
J.E.; et al. Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity. Cell 2015, 163, 160–173.
[CrossRef] [PubMed]
